# SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

> **NCT04050085** · PHASE1 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma
- Refractory Pancreatic Adenocarcinoma
- Stage IV Pancreatic Cancer AJCC v8

## Interventions

- **BIOLOGICAL:** Nivolumab
- **RADIATION:** Radiation Therapy
- **DRUG:** TLR9 Agonist SD-101

## Key facts

- **NCT ID:** NCT04050085
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-15
- **Primary completion:** 2021-12-03
- **Final completion:** 2022-05-14
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04050085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04050085, "SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04050085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*